title: Biotherapies in multiple sclerosis: a step toward remyelination and neuroprotection?
abstract: Multiple sclerosis (MS) is a complex disease of the central nervous system (CNS), characterized by CNS-restricted inflammation with subsequent demyelination and neurodegeneration. Current disease-modifying therapies efficiently reduce relapse rate and new lesions appearance, but still fail to impact the progressive course of the disease. There is a great need for the avenue of new therapies aimed at promoting myelin repair or reducing neurodegeneration that should result in the prevention of neurological disability in this chronic disease. This review will focus on the potentials and limitations of biotherapies that are currently developed for the promotion of CNS repair in MS, either monoclonal antibodies targeting axonal growth and remyelination, or cell therapies aimed at replacing the depleted myelinating cells within the CNS. As other researches aimed at promoting neuroprotection or remyelination are following a classical pharmacological approach, they will not be described in this review, which will focus on antibody-based therapies and cell therapies.
authors.affiliation: Sorbonne universités, UPMC Univ Paris 06, UMR S 1127, and Inserm U 1127, and CNRS UMR 7225, and ICM, 4, place Jussieu, 75013 Paris, France; 75005 Paris, France.
authors.forename: A-L
authors.initials: AL
authors.lastname: Dubessy
authors.affiliation: Sorbonne universités, UPMC Univ Paris 06, UMR S 1127, and Inserm U 1127, and CNRS UMR 7225, and ICM, 4, place Jussieu, 75013 Paris, France; 75005 Paris, France.
authors.forename: V
authors.initials: V
authors.lastname: Zujovic
authors.affiliation: Sorbonne universités, UPMC Univ Paris 06, UMR S 1127, and Inserm U 1127, and CNRS UMR 7225, and ICM, 4, place Jussieu, 75013 Paris, France; 75005 Paris, France; 75005 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Papeix
authors.affiliation: Sorbonne universités, UPMC Univ Paris 06, UMR S 1127, and Inserm U 1127, and CNRS UMR 7225, and ICM, 4, place Jussieu, 75013 Paris, France; 75005 Paris, France; Université Pierre-et-Marie-Curie, hôpital Tenon-HUEP, AP-HP, 4, rue de la Chine, 75020 Paris, France. Electronic address: bruno.stankoff@tnn.aphp.fr.
authors.forename: B
authors.initials: B
authors.lastname: Stankoff
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001691:Biological Therapy / Q000379:methods*; D003711:Demyelinating Diseases / Q000628:therapy; D006801:Humans; D009103:Multiple Sclerosis / Q000628:therapy*; D009186:Myelin Sheath / Q000502:physiology*; D009416:Nerve Regeneration / Q000502:physiology*; D018696:Neuroprotective Agents / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D018696:Neuroprotective Agents
keywords: La remyélinisation; Les cellules souches; Lingo1; Multiple sclerosis; Nogo; Remyelination; Sclérose en plaques; Stem cells; Transplantation